The 2024 American Society of Clinical Oncology (GU ASCO 2024) Genitourinary Cancers Symposium brought together leading cancer specialists from around the world to discuss the latest breakthroughs in treating genitourinary cancers, especially kidney cancer. The focus was on immunotherapy and combination treatments, offering promising new options for patients with advanced and high-risk tumors. The symposium also highlighted advancements in patient care, including a new tool to assess quality of life in people with metastatic kidney cancer.
Keywords: The American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium; adjuvant therapy; improved diagnostics; kidney cancer; systemic therapies; trials-in-progress.